CB

Castalysis Bioscience at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Castalysis Bioscience brings 2 presentations to ESGCT 2026 in Hamburg. Its work pairs a very small Cas12n editor with engineered lipid nanoparticles for editing inside the body. One project edits the FXII gene as a treatment for hereditary angioedema, and another tunes cationic lipids to get more editing per dose.

OrganizationESGCT 2026 Attendance
CB
Castalysis Bioscience
Biotech
Develops in vivo genome editing with an ultra-compact Cas12n nuclease delivered by engineered lipid nanoparticles, including a hereditary angioedema program.
Poster
Wed Oct 28
1:30pm–3:30pm
In Vivo FXII Gene Editing for Hereditary Angioedema Using an Ultra-Compact and Potentially Low-Immunogencity Cas12n Platform
Gene Editing
Poster
Thu Oct 29
2:00pm–4:00pm
Cationic Lipid-Engineered LNPs Improve Intracellular Delivery and In Vivo Genome Editing Efficiency of Ultra-Compact Cas12n Nuclease
Gene Editing

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Castalysis Bioscience

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction